60 results
8-K
EX-4.3
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant … the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant
8-K
EX-4.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation … (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders
8-K
EX-99.2
PCSA
Processa Pharmaceuticals Inc
1 Jun 20
Entry into a Material Definitive Agreement
7:01am
has a narrow therapeutic window and dose limiting adverse effects, including a FDA “Black Box” warning for both neutropenia and severe diarrhea
8-K
EX-99.2
pkj9jgen
8 Nov 22
Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
4:07pm
8-K
EX-99.1
5tjcvg91 66b3te
14 Dec 22
Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
11:22am
10-K
EX-10.17
oxryx80 irjp5
27 Mar 14
Annual report
12:00am
424B3
k4z9ybd a6
13 Nov 18
Prospectus supplement
9:39pm
8-K
EX-99.1
i3s9rem0c oa
9 Jan 14
Entry into a Material Definitive Agreement
12:00am